Oramed Pharmaceuticals Statistics

Total Valuation

TLV:ORMP has a market cap or net worth of ILS 311.79 million. The enterprise value is -160.78 million.

Market Cap	311.79M
Enterprise Value	-160.78M

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	40.85M
Shares Outstanding	n/a
Shares Change (YoY)	-0.05%
Shares Change (QoQ)	+1.38%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	32.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	41.87
PB Ratio	0.60
P/TBV Ratio	0.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	1.53
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	4.12

Financial Position

The company has a current ratio of 23.94, with a Debt / Equity ratio of 0.00.

Current Ratio	23.94
Quick Ratio	23.83
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	-54.86

Financial Efficiency

Return on equity (ROE) is -18.51% and return on invested capital (ROIC) is -5.29%.

Return on Equity (ROE)	-18.51%
Return on Assets (ROA)	-5.10%
Return on Invested Capital (ROIC)	-5.29%
Return on Capital Employed (ROCE)	-10.08%
Revenue Per Employee	1.86M
Profits Per Employee	-26.29M
Employee Count	4
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

In the past 12 months, TLV:ORMP has paid 14.03 million in taxes.

Income Tax	14.03M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.75% in the last 52 weeks. The beta is 1.62, so TLV:ORMP's price volatility has been higher than the market average.

Beta (5Y)	1.62
52-Week Price Change	+0.75%
50-Day Moving Average	796.10
200-Day Moving Average	844.32
Relative Strength Index (RSI)	45.58
Average Volume (20 Days)	11,173

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.99

Income Statement

In the last 12 months, TLV:ORMP had revenue of ILS 7.45 million and -105.14 million in losses. Loss per share was -2.65.

Revenue	7.45M
Gross Profit	48,406
Operating Income	-53.32M
Pretax Income	-91.27M
Net Income	-105.14M
EBITDA	-52.69M
EBIT	-53.32M
Loss Per Share	-2.65

Full Income Statement

Balance Sheet

The company has 486.45 million in cash and 1.12 million in debt, giving a net cash position of 485.33 million.

Cash & Cash Equivalents	486.45M
Total Debt	1.12M
Net Cash	485.33M
Net Cash Per Share	n/a
Equity (Book Value)	520.90M
Book Value Per Share	12.83
Working Capital	469.10M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -38.93 million and capital expenditures -70,747, giving a free cash flow of -39.00 million.

Operating Cash Flow	-38.93M
Capital Expenditures	-70,747
Free Cash Flow	-39.00M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	0.65%
Operating Margin	-715.95%
Pretax Margin	-1,225.60%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

TLV:ORMP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.05%
Shareholder Yield	n/a
Earnings Yield	-33.72%
FCF Yield	-12.51%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:ORMP has an Altman Z-Score of 6.53 and a Piotroski F-Score of 3.

Altman Z-Score	6.53
Piotroski F-Score	3